The EU CHMP will review its negative opinion of Human IgG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech, intended to treat symptoms of advanced colorectal cancer.-XBiotech
On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for Human IgG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech, intended for treating debilitating symptoms of advanced colorectal cancer. The company that applied for authorisation is XBiotech Germany GmbH. It may request a reexamination of the opinion within 15 days of receipt of notification of this negative opinion.
The company has applied for a marketing authorisation for this medicine and has requested a reexamination of the CHMP�s May 2017 opinion. Upon receipt of the grounds of the request, the CHMP will re-examine its opinion and issue a final recommendation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.